Lupin, Aurobindo Pharma hit fresh 52-week lows

Lupin was down 2.5% at Rs 1,305 and Aurobindo Pharma down 2.3% at Rs 592 on BSE in intra-day trade.

Shares of Lupin and Aurobindo Pharma hit their respective fresh 52-week lows, extending their losses on BSE, after US drug regulator issued Form 483 with observations.

Lupin, the largest loser among Sensex pack, was down 2.5% at Rs 1,305, after the company on Friday said that the US Food and Drug Administration (USFDA) issued Form 483 with three observations for its Goa facility.

“Recently, the company’s Goa manufacturing facility underwent an inspection by the USFDA. The said inspection was completed on April 7, 2017, subsequently to which, the USFDA issued Form 483 citing three observations,” Lupin said in a BSE